Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Brigatinib (Alunbrig) in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) in Argentina
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Takeda
- 14 Apr 2023 Status changed from recruiting to completed.
- 16 Feb 2023 Planned End Date changed from 30 Jan 2023 to 31 Mar 2023.
- 16 Feb 2023 Planned primary completion date changed from 30 Jan 2023 to 31 Mar 2023.